Research led by Gary Peltz at Stanford utilizes Co-Scientist to identify existing drugs for liver fibrosis treatment. The AI selected promising candidates, including vorinostat, which showed significant efficacy in lab tests.
Liver fibrosis is a scarring disease that can progress to cirrhosis and is responsible for more than 1.4 million deaths worldwide each year. Effective treatments are necessary to slow, stop, or reverse the progression of liver damage.
Geneticist Gary Peltz at Stanford University has leveraged the AI tool Co-Scientist to search the existing literature for medications that could be repurposed for treating liver fibrosis. This approach aims to accelerate the discovery process and explores the potential of already-known drugs.
Peltz's research, published in Advanced Science, involved testing five drug candidates—three suggested by Co-Scientist and two selected by Peltz. The lab tests revealed that Co-Scientist's selections were more effective; two of the AI’s picks successfully inhibited fibrosis and promoted liver cell regeneration.
Among the candidates identified by Co-Scientist, vorinostat, a cancer treatment, stood out by blocking 91% of a liver damage response linked to fibrosis. This finding illustrates the potential of using AI to discover novel applications for existing drugs in treating complex diseases. Peltz advocates for further investigation of these findings to develop new anti-fibrotic therapies.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
Research led by Gary Peltz at Stanford utilizes Co-Scientist to identify existing drugs for liver fibrosis treatment. The AI selected promising candidates, including vorinostat, which showed significant efficacy in lab tests.